I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.

Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

Reports of cases detail the development of thyroid eye disease 3-5 years following treatment of MS with immunomodulatory ...

Mavenclad may help manage coexisting autoimmune diseases alongside MS, potentially reducing the need for extra drugs.

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...

MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Over 20 FDA-approved disease-modifying therapies exist, ...

BUFFALO, N.Y. (WIVB) — More than a thousand people gathered at Terminal B at the Outer Harbor with one goal in mind Saturday morning — making the step forward toward finding a cure for multiple ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...